CNS Drugs

, Volume 24, Issue 10, pp 805–810

Abuse-Deterrent and Tamper-Resistant Opioid Formulations

What is their Role in Addressing Prescription Opioid Abuse?
  • Jennifer P. Schneider
  • Michele Matthews
  • Robert N. Jamison
Leading Article

DOI: 10.2165/11584260-000000000-00000

Cite this article as:
Schneider, J.P., Matthews, M. & Jamison, R.N. CNS Drugs (2010) 24: 805. doi:10.2165/11584260-000000000-00000


About one in every three individuals will experience chronic pain in their lifetime, and opioids are known to be an effective means to treat this condition. Much attention, however, has been given to the fact that prescription opioid analgesics are some of the most frequently abused drugs, and misuse is prominent in patients with chronic pain. Several new opioid formulations that are designed to prevent or deter the abuse of opioids are currently in development, and two have been approved for marketing (morphine sulphate co-formulated with naltrexone hydrochloride [Embeda®] and a new formulation of the extended-release oxycodone [OxyContin®]).

In this article, we review the various types of abuse-deterrent and tamper-resistant formulations in clinical development. We believe that continued advances in opioid formulations can help mitigate risk for those with legitimate need for pain control, but only if used rationally in the context of good clinical practice.

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Jennifer P. Schneider
    • 1
  • Michele Matthews
    • 2
    • 3
  • Robert N. Jamison
    • 3
  1. 1.Arizona Community PhysiciansTucsonUSA
  2. 2.Massachusetts College of Pharmacy and Health SciencesBostonUSA
  3. 3.Pain Management Center, Departments of Anesthesia and PsychiatryBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA
  4. 4.Pain Management Center, Brigham and Women’s Hospital, Harvard Medical SchoolBostonUSA